3,3-Dimethylpiperidine → HCID 67064740, compound
Reaction equation
Cl[C:2]1[N:7]2[N:8]=[CH:9][CH:10]=[C:6]2[N:5]=[C:4]([NH:11][C:12](=[O:23])[C:13]2[CH:18]=[CH:17][C:16]([C:19]([OH:22])([CH3:21])[CH3:20])=[CH:15][CH:14]=2)[CH:3]=1.[CH3:24][C:25]1([CH3:31])[CH2:30][CH2:29][CH2:28][NH:27][CH2:26]1>CN1C(=O)CCC1.CS(C)=O.CO>[CH3:24][C:25]1([CH3:31])[CH2:30][CH2:29][CH2:28][N:27]([C:2]2[N:7]3[N:8]=[CH:9][CH:10]=[C:6]3[N:5]=[C:4]([NH:11][C:12](=[O:23])[C:13]3[CH:18]=[CH:17][C:16]([C:19]([OH:22])([CH3:21])[CH3:20])=[CH:15][CH:14]=3)[CH:3]=2)[CH2:26]1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 3
Procedure
A solution of N-(7-chloropyrazolo[1,5-a]pyrimidin-5-yl)-4-(2-hydroxypropan-2-yl)benzamide (2D, 50 mg, 0.151 mmol) and 3,3-dimethylpiperidine (34 mg, 0.302 mmol) in NMP (0.950 mL) was stirred at 85° C. overnight. After cooling to room temperature, the mixture was diluted with a few drops of DMSO and methanol, and was then purified by preparatory HPLC, 40-65% (MeCN/H2O gradient+0.01% TFA). Lyophilization of the combined fractions gave the titled compound as a white solid (33 mg, 54%). 1H NMR (400 MHz, DMSO-d6) δ ppm 0.99 (s, 6H) 1.45 (s, 6H) 1.50 (t, J=6.06 Hz, 2H) 1.80 (br. s., 2H) 3.51 (s, 2H) 3.65 (t, J=5.05 Hz, 2H) 6.33 (d, J=2.02 Hz, 1H) 7.39 (s, 1H) 7.60 (d, J=8.34 Hz, 2H) 8.00 (d, J=8.34 Hz, 2H) 8.08 (d, J=2.02 Hz, 1H) 10.85 (s, 1H). ESI-MS: m/z 408.3 (M+H)+.
Workup
- customwas then purified by preparatory HPLC, 40-65% (MeCN/H2O gradient+0.01% TFA)
Sources & evidence
- ORD record
- ord-dcd6e76ae8cf40289deaab828274514d
- Source dataset
- uspto-grants-2014_12
- Patent number
- US08921358B2
Reaction notes
Loading…